18 THERAPY Low-dose lansoprazole prevents duodenal ulcer recurrence A maintenance regimen of lansoprazole 15 mg/day can prevent duodenal ulcer recurrence, report researchers from the Lansoprazole Study Group in the US. In this study, 186 patients with healed duodenal ulcers (as documented on endoscopy) were randomised to receive maintenance therapy with lansoprazole 15 mg/day or placebo. Therapy continued for 12 months or until ulcer recurrence. Delayed ulcer recurrence The median time to ulcer recurrence was> 12 months among lansoprazole recipients, compared with < 3 months among placebo recipients; the between-group difference was statistically significant. Among the 169 evaluable patients, 84% of lansoprazole recipients experienced no ulcer recurrence, compared with 39% of placebo recipients. The researchers comment that proton-pump inhibitors are not approved in the US for use as maintenance therapy in patients with nonrefractory ulcers. However, they suggest that long-term use of lansoprazole 15 mg/day 'may be a desirable alternative to therapy with Hz-receptor antagonists in patients who are not infected with H. [Helicobacter] pylori, are resistant or intolerant to, or poor candidates for, eradication therapy'. Lanza F, Goff J, Silvers D, Wmters J, Lansoprazole Study Group. Prevention of duodenal ulcer recurrence with 15mg JansoprazoJe: a double-blind placebo-controlled study. Digestive Diseases and Sciences 42: 2529-2536, Dec 1997 800637850 Inphanna e Z1 Feb 1998 No. 1125 1173-832419811125-000181$01 .Or!' Adl. International Limited 1998. All rights reserved

Low-dose lansoprazole prevents duodenal ulcer recurrence

Download PDF Report

View
222
Download
2

Embed Size (px)

Citation preview

18 THERAPY

Low-dose lansoprazole prevents duodenal ulcer recurrence

A maintenance regimen of lansoprazole 15 mg/day can prevent duodenal ulcer recurrence, report researchers from the Lansoprazole Study Group in the US.

In this study, 186 patients with healed duodenal ulcers (as documented on endoscopy) were randomised to receive maintenance therapy with lansoprazole 15 mg/day or placebo. Therapy continued for 12 months or until ulcer recurrence.

Delayed ulcer recurrence The median time to ulcer recurrence was> 12

months among lansoprazole recipients, compared with < 3 months among placebo recipients; the between-group difference was statistically significant.

Among the 169 evaluable patients, 84% of lansoprazole recipients experienced no ulcer recurrence, compared with 39% of placebo recipients.

The researchers comment that proton-pump inhibitors are not approved in the US for use as maintenance therapy in patients with nonrefractory ulcers. However, they suggest that long-term use of lansoprazole 15 mg/day 'may be a desirable alternative to therapy with Hz-receptor antagonists in patients who are not infected with H. [Helicobacter] pylori, are resistant or intolerant to, or poor candidates for, eradication therapy'.

Lanza F, Goff J, Silvers D, Wmters J, Lansoprazole Study Group. Prevention of duodenal ulcer recurrence with 15mg JansoprazoJe: a double-blind

placebo-controlled study. Digestive Diseases and Sciences 42: 2529-2536,

Dec 1997 800637850